Inhibition of inducible nitric oxide synthesis by azathioprine in a macrophage cell line

Life Sciences

Volumn 79, Issue 4, 2006, Pages 374-381

  Moeslinger, Thomas ^a   Friedl, Roswitha ^a   Spieckermann, Paul Gerhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Azathioprine; Inducible nitric oxide synthase; Murine macrophages

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; DACTINOMYCIN; IMIDAZOLINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN P50; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN P65; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; LIPOPOLYSACCHARIDE; MERCAPTOPURINE; MESSENGER RNA; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOTINYLATION; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE EXPRESSION; IC 50; IMMUNOBLOTTING; INCUBATION TIME; INTRACELLULAR TRANSPORT; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; AZATHIOPRINE; CELL LINE; CELL NUCLEUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON REGULATORY FACTOR-1; INTERFERON-BETA; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MURINAE;

EID: 33744512186     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.015     Document Type: Article

References (47)

1. Adams D.H., Wang L.F., Neuberger J.M., and Elias E. Inhibition of leukocyte chemotaxis by immunosuppressive agents. Specific inhibition of lymphocyte chemotaxis by cyclosporine. Transplantation 50 5 (1990) 845-850
2. Allison A.C., and Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 2-3 (2000) 85-118
3. Attur M.G., Patel R., Thakker G., Vyas P., Levartovsky D., Patel P., Naqvi S., Raza R., Patel K., Abramson D., Bruno G., Abramson S.B., and Amin A.R. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflammation Research 49 1 (2000) 20-26
4. Balachandran I., and Galagan K.S. Cervical carcinoma in situ associated with azathioprine therapy. A case report and literature review. Acta Cytologica 28 6 (1984) 699-702
5. Berenbaum M.C. Is azathioprine a better immunosuppressive than 6-mercaptopurine?. Clinical and Experimental Immunology 8 1 (1971) 1-8
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemstry 72 (1976) 248-254
7. Burgos Revilla F.J., Pascual Santos J., Marcen Letosa R., Gomez Do Santos V., Sanchez-Encinas M., and Escudero Barrilero A. Renal transplantation and urinary infection. (Review). Actas Urologicas Espanolas 23 2 (1999) 95-104
8. Cattan S., Wendum D., Chazouilleres O., Schmitz J., and Gendre J.P. Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Human Pathology 31 7 (2000) 874-876
9. Chan T.M., Li F.K., Wong R.W., Wong K.L., Chan K.W., and Cheng I.K. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 71 3 (1995) 321-327
10. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 1 (1987) 156-159
11. Confavreux C., Saddier P., Grimaud J., Moreau T., Adeleine P., and Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46 6 (1996) 1607-1612
12. Cooke J.P., and Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annual Review of Medicine 48 (1997) 489-509
13. Crawford D.J., Maddocks J.L., Jones D.N., and Szawlowski P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. Journal of Medicinal Chemistry 39 14 (1996) 2690-2695
14. Cuffari C., Hunt S., and Bayless T.M. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Alimentary Pharmacology & Therapeutics 14 8 (2000) 1009-1014
15. Drath D.B., and Kahan B.D. Phagocytic cell function in response to immunosuppressive therapy. Archives of Surgery 119 2 (1984) 156-160
16. Dunnill M.S., Gatter K.C., Mason D.Y., and Morris P.J. Immunosuppression and thrombosis in renal transplantation: an immunohistological study. Histopathology 16 1 (1990) 79-82
17. Dusting G.J., and Macdonald P.S. Endogenous nitric oxide in cardiovascular disease and transplantation. Annals of Medicine 27 3 (1995) 395-406
18. Elion G.B. Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Federation Proceedings 26 3 (1967) 898-904
19. el-Yazigi A., and Wahab F.A. Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. Journal of Clinical Pharmacology 33 6 (1993) 522-526
20. 15N] nitrate in biological fluids. Analytical Biochemistry 126 1 (1982) 131-138
21. Hamalainen M., Lahti A., and Moilanen E. Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. European Journal of Pharmacology 448 2-3 (2002) 239-244
22. Hibbs Jr. J.B., Taintor R.R., Vavrin Z., and Rachlin E.M. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochemical and Biophysical Research Communications 157 1 (1988) 87-94
23. Homo-Delarche F., Bach J.F., and Dardenne M. In vitro inhibition of prostaglandin production by azathioprine and 6-mercaptopurine. Prostaglandins 35 4 (1988) 479-491
24. Inoue T., Hamada Y., Takeshita K., Fukushima K., and Higaki M. KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis. Journal of Rheumatology 28 6 (2001) 1229-1237
25. Kahan B.D. The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring. Therapeutic Drug Monitoring 17 6 (1995) 560-563
26. Kilbourn R.G., and Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. Journal of the National Cancer Institute 82 9 (1990) 772-776
27. Kwak J.Y., Han M.K., Choi K.S., Park I.H., Park S.Y., Sohn M.H., Kim U.H., McGregor J.R., Samlowski W.E., and Yim C.Y. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cellular Immunology 203 2 (2000) 84-94
28. Lin Y.T., Yang Y.H., Tsai M.J., and Chiang B.L. Long-term effects of azathioprine therapy for juvenile rheumatoid arthritis. Journal of the Formosan Medical Association 99 4 (2000) 330-335
29. Lloyd Jones D.M., and Bloch K.D. The vascular biology of nitric oxide and its role in atherogenesis. Annual Review of Medicine 47 (1996) 365-375
30. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annual Review of Immunology 15 (1997) 323-350
31. Marletta M.A. Nitric oxide synthase structure and mechanism. Journal of Biological Chemistry 268 17 (1993) 12231-12234
32. McAdam L., Paulus H.E., and Peter J.B. Adenocarcinoma of the lung during azathioprine therapy. Arthritis and Rheumatism 17 1 (1974) 92-94
33. Oguz Y., Bulucu F., Oktenli C., Doganci L., and Vural A. Infectious complications in 135 Turkish renal transplant patients. Central European Journal of Public Health 10 4 (2002) 153-156
34. Palmer R.M., Ashton D.S., and Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 333 6174 (1988) 664-666
35. Prabhakar S.S., Zeballos G.A., MontoyaZavala M., and Leonard C. Urea inhibits inducible nitric oxide synthase in macrophage cell line. American Journal of Physiology 42 6 (1997) C1882-C1888
36. Raij L., and Shultz P.J. Endothelium-derived relaxing factor, nitric oxide: effects on and production by mesangial cells and the glomerulus. Journal of the American Society of Nephrology 3 8 (1993) 1435-1441
37. Rosenau C., Emery D., Kaboord B., and Qoronfleh M.W. Development of a high-throughput plate-based chemiluminescent transcription factor assay. Journal of Biomolecular Screening 9 4 (2004) 334-342
38. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. American Journal of Gastroenterology 91 3 (1996) 423-433
39. Schmitt K., Pfeiffer U., Stiehrle H.E., and Thuermann P.A. Absence of azathioprine hypersensitivity after administration of its active metabolite 6-mercaptopurine. Acta Dermato-Venereologica 80 2 (2000) 147-148
40. Shultz P.J., and Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. Journal of Clinical Investigation 90 5 (1992) 1718-1725
41. Simmons W.W., Ungureanu-Longrois D., Smith G.K., Smith T.W., and Kelly R.A. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and l-arginine transport. Journal of Biological Chemistry 271 39 (1996) 23928-23937
42. Vaziri N.D., Ismail M., Martin D.C., and Gonzales E. Blood coagulation, fibrinolytic and inhibitory profiles in renal transplant recipients: comparison of cyclosporine and azathioprine. International Journal of Artificial Organs 15 6 (1992) 365-369
43. Waddington S., Cook H.T., Reaveley D., Jansen A., and Cattell V. l-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney International 49 4 (1996) 1090-1096
44. Westberg G., Shultz P.J., and Raij L. Exogenous nitric oxide prevents endotoxin-induced glomerular thrombosis in rats. Kidney International 46 3 (1994) 711-716
45. Wolfhagen F.H., van Hoogstraten H.J., van Buuren H.R., van Berge-Henegouwen G.P., ten Kate F.J., Hop W.C., van der Hoek E.W., Kerbert M.J., van Lijf H.H., den Ouden J.W., Smit A.M., de Vries R.A., van Zanten R.A., and Schalm S.W. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. Journal of Hepatology 29 5 (1998) 736-742
46. Worthington J., Robson T., Scott S., and Hirst D. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Therapy 19 (2005) 19
47. Xie Q.W., Cho H.J., Calaycay J., Mumford R.A., Swiderek K.M., Lee T.D., Ding A., Troso T., and Nathan C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256 5054 (1992) 225-228